ClinicalTrials.gg
CompletedNCT01131780Updated Jun 14, 2010

Bioequivalency Study of Ibuprofen 200 mg and Pseudoephedrine HCL 30 mg Tablets of Dr. Reddy's Under Fasting Conditions

A Phase 1 interventional study of Ibuprofen + Pseudoephedrine Hydrochloride in Healthy, sponsored by Dr. Reddy's Laboratories Limited. Completed at 1 site in India. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-06-14.

Sponsored by Dr. Reddy's Laboratories Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The purpose of this study is to assess the bioequivalence of Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg under fasting conditions.

Read the detailed description

This study assess the bioequivalence of Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets of Dr. Reddy's and Advil® Cold and Sinus Caplets of Wyeth Consumer Healthcare in healthy human adult subjects with the single oral administration under fasting conditions with a washout period of 7 days.

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • Crossover
  • Ibuprofen and Pseudoephedrine
03

In context

Lead sponsor

Dr. Reddy's Laboratories Limited is the lead sponsor of 224 studies on the registry; 2 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 11 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy human subjects between 18-50 years of age (inclusive), weighing as per the standard height and weight chart of Life Insurance Corporation of India (II Underweight and Overweight Min. \& Max. Chart)
  • Subjects who have no evidence of underlying disease during screening medical history and whose physical examination is performed within 21 days to commencement of the study.
  • Subjects whose screening laboratory values are within normal limits or considered by the physician/Principal Investigator to be of no clinical significance.
  • given in written form according to section 10.3 of the protocol.
  • Female Subjects:

    1. of child bearing potential practicing an acceptable method of for the duration of study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.
    2. for at least 1 year.
    3. surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of significant:

    • Cardiovascular, pulmonary, hepatic, renal hematological; gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.
    • Alcohol dependence, alcohol abuse or drug abuse within past one year.
    • Moderate to heavy smoking (> 10 cigarettes/day) or on assumption of tobacco products.
    • History of difficulty in swallowing.
    • illness within 4 weeks before the start of the study
    • Asthma, urticaria or other allergic type reactions after taking any medication.
  2. Subjects who, through completion of the study, would have donated in excess of:

    • 500ml of blood in 14 days, or
    • 500 - 800 m l of blood in 14 days (unless approved by the Principal Investigator)
    • 1000 ml of blood in 90 days
    • 1250 ml of blood in 120 days
    • 1500 ml of blood in 180 days
    • 2000 ml of blood in 270 days
    • 2500 ml of blood in 1 year
  3. Participation in another clinical trial within the preceding 28 days of study start.
  4. Subjects who have:

    • Systolic blood pressure less than 90 mm of Hg and more than 150 mm of Hg
    • Diastolic blood pressure less than 60 m of Hg and more than 95 mm of Hg. Minor deviations (1-3 mm Hg) at check-in may be acceptable at the discretion of the physician/investigator
    • Pulse rate below 50/min. and above 105/min.
  5. Female volunteers demonstrating a positive pregnancy screen or currently breast-feeding.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Ibuprofen + Psuedoephedrine Hydrochloride

    Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets

    Drug: Ibuprofen + Pseudoephedrine Hydrochloride

  • Active comparator
    Advil® Cold and Sinus

    Advil® Cold and Sinus Tablets of Wyeth Consumer Healthcare

    Drug: Ibuprofen + Pseudoephedrine Hydrochloride

Interventions

  • DrugIbuprofen + Pseudoephedrine Hydrochloride

    Drug pages: Ibuprofen · Pseudoephedrine

    Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets

    Also known as: Advil® Cold and Sinus

06

What researchers measure

Primary outcomes

  1. Bioequivalence based on Cmax and AUC parameters

    Time frame: 2 months

07

Study locations

1 site
  • Lotus Labs Pvt. Ltd.
    Bangalore, Karnataka 560034, India
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004, a primary completion of Oct 2004 and a completion of Nov 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2010
First posted
May 27, 2010
Start
Oct 2004
Primary completionActual
Oct 2004
CompletionActual
Nov 2004
Last update
Jun 14, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01131780
First posted
May 27, 2010
Start date
Oct 2004
Primary completion
Oct 2004
Completion
Nov 2004
Last update
Jun 14, 2010

Study contacts

Vijayanthi G, MBBS, MD
principal investigator · Lotus Labs Pvt. Ltd.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibuprofen · Pseudoephedrine

Start the discussion